Papatheodoridi M. Rates and predictors of HBsAg loss after discontinuation of effective long-term Entecavir or Tenofovir therapy in non-cirrhotic HBeAg-negative Chronic Hepatitis B patients: Results from the DARING-B prospective Greek study. PS-159.
Aangepaste orale 9-maandenregimes voor rifampicine-resistente tuberculose
jan 2025 | Bacteriële infecties, Tuberculose